SourceOne Completes Phase I Of Sytrinol Long-Term Clinical Trial

SourceOne Global partners recently completed the first of three phases of a double-blind, randomized 24-week study on 120 hypercholesterolemic subjects. The results from the completed 12-week, phase I, Sytrinol clinical trial are consistent with previous clinical studies on Sytrinol’s heart health benefits. Sytrinol is a patented, proprietary, branded ingredient from SourceOne. More than 12 years of research, including in vitro, in vivo and clinical studies have demonstrated that Sytrinol helps maintain healthy cholesterol, LDL cholesterol and triglyceride levels. Unlike ingredients that attempt to block the absorption of cholesterol in the gastrointestinal tract, Sytrinol works to balance cholesterol production in the liver.